SeamlessBio — EMA/410/01 Compliant · GMP Documented
CAR-T Cell Manufacturing — Serum, Media & Single-Use Bag Selection Guide
Five CAR-T therapies have received FDA approval since 2017. Every stage — T cell isolation, activation, transduction, expansion, formulation — requires specific biological materials whose grade and regulatory documentation directly determine process success and compliance. This guide covers the complete workflow from R&D to GMP Phase I/II.
EMA/410/01 — The Regulatory Baseline for Serum in CAR-T:
EMA guideline EMA/410/01 explicitly discourages FBS in ATMP manufacturing. Human Serum AB OTC Male is the preferred ancillary material for ex vivo T cell expansion. Ph. Eur. 5.2.12 documentation required for all human-derived ancillary materials in GMP-phase manufacturing. SeamlessBio provides full documentation packages on request.
CAR-T Manufacturing — Phase Overview & Product Requirements
| Phase | Process Step | Recommended Product | Key Specification |
|---|---|---|---|
| R&D Process Development | T cell isolation, activation screening, vector optimisation | FBS Ultra Low IgG <5 µg/mL | Low IgG prevents FcR competition in T cell activation assays — cost-effective for screening |
| R&D → GMP T Cell Activation | CD3/CD28 stimulation, IL-2, pre-expansion | Human Serum AB OTC Male or Human Serum AB HI | OTC: max growth factors from platelet degranulation. HI: when complement must be inactivated during activation |
| GMP Ex Vivo T Cell Expansion | Large-scale CAR-T expansion in static bags or bioreactors | Human Serum AB OTC Male — 5–10% | Gold standard. AB type (no anti-A/B lysis), male donors (no hormonal variability), off-the-clot (max native growth factors). EMA/410/01 preferred. |
| GMP Bioreactor Expansion | Rocking bag bioreactor scale-up (0.5–50 L) | Rocker Bags 0.5–200 L | Compatible with common rocking platforms. ISO 13485. Gamma sterilised ≥25 kGy ISO 11137. Custom port configurations. |
| GMP Xeno-Free / Serum-Free | Defined serum-free T cell expansion medium supplement | rHSA Premium Grade | Xeno-free albumin carrier. Defined, lot-consistent. No donor variability. ISO 13485 documentation. |
| GMP Media & Buffer Prep | Media preparation, buffer formulation, storage | 2D Single-Use Bags 150 mL–50 L | Closed system. Drop-in for market-standard 2D bags. GMP documentation. ISO 13485 Germany. |
| GMP Harvest & Formulation | Cell harvest, wash, cryopreservation medium formulation | 2D Single-Use Bags + rHSA in formulation buffer | Closed transfer into gamma-sterilised bags. HSA/rHSA prevents cell surface adsorption. |
| QC Release Testing | Cytotoxicity, ELISpot, ADCC potency assay | FBS VLE ≤1 EU/mL + Human Serum AB HI | VLE for ELISpot background. Human Serum AB HI for PBMC-based release assays. |
Why Human Serum AB Male OTC is the CAR-T Gold Standard
Each specification is mechanistically justified — not arbitrary.
| Specification | Why It Matters in CAR-T |
|---|---|
| Type AB | No anti-A or anti-B antibodies. In CAR-T expansion where donor T cells from any blood group are expanded, non-AB serum causes anti-A/B-mediated agglutination and lysis of residual red blood cells — elevating background cell death and compromising yield. |
| Male donors only | Female donor serum contains oestrogen and progesterone that vary with the menstrual cycle. These hormones affect T cell activation thresholds and cytokine production — introducing lot-to-lot yield variability. Male-only pools eliminate this hormonal interference. |
| Off-the-Clot (OTC) | OTC preserves maximum platelet-derived growth factors released during clot formation: PDGF, TGF-β, EGF, IGF-1. These directly amplify T cell activation signals and expansion yield. Centrifuged or platelet-poor preparations have significantly lower growth factor content. |
| Human (not bovine) | EMA/410/01 explicitly discourages FBS. FBS introduces bovine xenogenic antigens that sensitise expanded T cells and generate anti-bovine immune responses in patients post-infusion. Human serum eliminates xenogenic antigen exposure and provides a physiologically matched matrix. |
Human Serum Portfolio for CAR-T — All Grades Explained
| Product | CAR-T Application | Phase | Key Advantage |
|---|---|---|---|
| Human Serum AB OTC Male | Ex vivo T cell expansion — primary medium supplement | R&D → GMP Phase I/II | Max growth factors. No anti-A/B. No hormonal variability. EMA/410/01 preferred. |
| Human Serum AB HI | T cell activation (complement-sensitive protocols). ELISpot and PBMC QC release assays. | R&D, QC | 56°C/30 min — complement destroyed. No complement-mediated T cell lysis during stimulation. |
| Human Platelet Lysate (hPL) | Xeno-free MSC expansion. T cell expansion for fully xeno-free GMP protocols. | GMP xeno-free | No animal-derived components. Higher MSC proliferation rate. EMA Annex I xeno-free compliant. |
| rHSA Premium Grade | Albumin supplement in defined xeno-free T cell medium. Formulation buffer. GMP cryopreservation. | GMP Phase I/II, xeno-free | No donor variability. No blood-borne pathogen risk. ISO 13485 documentation. |
FBS in CAR-T — When Still Used and Which Grade
⚠ EMA/410/01: FBS is discouraged in clinical CAR-T manufacturing. For Phase I/II CTA submissions, human serum or defined xeno-free media are the regulatory standard. FBS is still used in early research, process development, and non-clinical studies where EMA ATMP requirements do not apply.
| CAR-T Application | FBS Grade | Why This Grade |
|---|---|---|
| Early process development — T cell activation screening | FBS Ultra Low IgG <5 µg/mL | Bovine IgG occupies FcγR on T cells and APCs — directly interfering with CD3/CD28 stimulation signals. Ultra Low IgG eliminates this interference. |
| Tet-On/Tet-Off inducible CAR constructs, lentiviral packaging | FBS Tet-Free <10 ng/mL | Standard FBS contains tetracycline residues at 10–100 ng/mL — suppresses Tet-responsive promoters even at ng/mL levels. Most common hidden cause of failed inducible CAR constructs. |
| ADCC potency assay development | FBS Ultra Low IgG <5 µg/mL | Bovine IgG competes with therapeutic CAR construct for FcγR binding — must be eliminated from ADCC assay medium. |
| ELISpot / PBMC-based potency assays | FBS Very Low Endotoxin ≤1 EU/mL | Endotoxin activates monocytes — non-specific IFN-γ background masks CAR-T-specific cytotoxic response in ELISpot. |
| Non-clinical murine CAR-T studies | FBS Low Endotoxin ≤5 EU/mL | Standard grade for syngeneic mouse tumour models where human serum is not required. |
Single-Use Bags for CAR-T Manufacturing
| Product | Volume Range | CAR-T Application | Key Specification |
|---|---|---|---|
| Rocker Bag | 0.5–200 L | Ex vivo T cell expansion on rocking wave bioreactor (compatible with common rocking platforms) | EVA/LDPE or USP Class VI multilayer PE. Gamma sterilised ≥25 kGy. ISO 13485. Custom port configurations. |
| 2D Bioprocessing Bags | 150 mL–50 L | Media preparation, buffer storage, cell transfer, cryopreservation medium storage | USP Class VI. Gamma sterilised. Drop-in for market-standard 2D bags. ISO 13485 Germany. |
| 3D Bioprocessing Bags | 50–1,000 L | Large-volume media preparation for clinical-scale CAR-T manufacturing facilities | MPX tubing. Full GMP documentation package. Gamma sterilised. ISO 13485. |
Regulatory Documentation — What You Need for Phase I/II CAR-T
| Document | SeamlessBio | Regulatory Requirement |
|---|---|---|
| Certificate of Analysis (CoA) | ✅ Per lot — all products | Mandatory — all ancillary materials |
| Certificate of Origin (CoO) | ✅ Per lot | Mandatory — human-derived material traceability |
| TSE/BSE Statement | ✅ Included | EMA Eudralex Vol. 4 Part IV |
| Ph. Eur. 5.2.12 Declaration | ✅ On request | Human-derived ancillary materials for ATMP |
| Viral Testing Panel | ✅ Per lot — HIV, HBV, HCV, CMV, EBV, Parvovirus B19 | ICH Q5A — viral safety of human-derived materials |
| Batch reservation | ✅ Up to 36 months — no cost during evaluation phase | Process validation — same lot throughout Phase I/II campaign |
| Irradiation certificate (Bags) | ✅ Per shipment — ISO 11137 | Single-use bag sterility documentation |
Serum Transition: FBS → Human Serum in CAR-T Protocols
For laboratories transitioning from FBS-based to human serum-based CAR-T expansion, a validated stepwise approach minimises expansion disruption:
| Week | Medium Composition | Monitoring Parameters |
|---|---|---|
| Week 1 | 50% FBS Ultra Low IgG + 50% Human Serum AB OTC Male (same total serum %) | Viability, fold expansion, activation markers (CD25, CD69) |
| Week 2 | 25% FBS Ultra Low IgG + 75% Human Serum AB OTC Male | Growth curve comparison, cytokine profile (IFN-γ, IL-2, TNF-α) |
| Week 3+ | 100% Human Serum AB OTC Male at 5–10% | Confirm ≥95% viability, stable fold-expansion, phenotype maintenance (CD4/CD8, memory markers) |
| Optional | 5% → 2% → 0% serum with rHSA supplementation → fully serum-free xeno-free | Full serum-free protocol validation for GMP Phase I/II submission |
Frequently Asked Questions
Why is Human Serum AB Male OTC preferred over AB Female or mixed-gender pools?
Male-only donor serum eliminates hormonal variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production in a cycle-dependent manner. Mixed-gender or female pools introduce hormonal lot-to-lot variability that manifests as inconsistent CAR-T expansion yields between manufacturing runs — a critical quality issue in GMP production where process consistency is a regulatory requirement.
Can I use FBS for Phase I/II CAR-T trials?
EMA/410/01 discourages FBS in clinical ATMP manufacturing and requires justification if animal-derived ancillary materials are used. For Phase I/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional safety testing. SeamlessBio recommends transitioning to Human Serum AB OTC Male for all GMP-phase CAR-T manufacturing.
Why does FBS Tet-Free matter specifically for CAR-T development?
Standard FBS contains tetracycline residues at 10–100 ng/mL from bovine husbandry. Tet-On and Tet-Off inducible CAR constructs and lentiviral packaging systems are suppressed at concentrations as low as 1–10 ng/mL. Standard FBS can partially or completely suppress transgene induction — causing researchers to incorrectly conclude the construct is non-functional. FBS Tet-Free <10 ng/mL is the only correct grade for any Tet-regulated CAR-T application.
What batch size of Human Serum AB OTC Male for Phase I CAR-T?
For Phase I autologous CAR-T (typically 3–10 patient batches), a lot reservation of 500 mL to 2 L is usually sufficient at 5–10% serum in expansion medium. SeamlessBio holds batch reservations up to 36 months at no cost during the validation phase, allowing lot testing before commitment.
Which single-use bag size for CAR-T rocking bioreactor expansion?
For autologous CAR-T Phase I manufacturing, 0.5–5 L rocker bags are typical — matching cell numbers from a single patient apheresis. For allogeneic or iPSC-derived CAR-T at larger scale, 10–50 L bags are standard. SeamlessBio rocker bags are compatible with common rocking platforms in all sizes from 0.5 L to 200 L.
Request Free Test Volumes & GMP Documentation
Human Serum AB OTC Male lot-specific viral testing and Ph. Eur. 5.2.12 documentation available on request. Free samples for process development. Batch reservation for Phase I/II CAR-T programmes.
Email: info@seamlessbio.de | +49 851 37932226
English
Deutsch